[Usefulness of induction chemotherapy followed by chemo-radiotherapy for patients with advanced cervical esophageal cancer].
To obtain a good prognosis and preserve laryngeal function is one of the most important issues for patients with advanced cervical esophageal cancer. It is reported that induction chemotherapy (ICT) followed by concurrent chemoradiotherapy (CRT) is useful. We treated 8 consecutive patients with advanced cervical esophageal cancer by ICT and following CRT between 2003 and 2006. The regimen of ICT was FAP therapy (fluorouracil 1,000 mg/day and cisplatin 20mg/day on days 1-5, and doxorubicin 50mg/day on day 1) every 4 weeks. After 2-4 courses of FAP therapy, low-dose FP-CRT (fluorouracil 200mg/24 hours/day and cisplatin 5mg/day with radiation of 60-66 Gy, 2 Gy/day) were given. Effect of ICT was PR in 5 cases, SD in 1 case, and PD in 2 cases. Furthermore, the effect of ICT+CRT was CR in 5 cases and PD in 3 cases. The one-year survival rate was 62. 5%. Grade 3 hematological toxicity related to ICT was observed in 1 patient (12.5%). Grade 3 anorexia and esophagitis related to CRT were observed in 3 patients (37.5%) and 2 patients (25.0%), respectively. Radiation pneumonitis as a late toxicity occurred in 1 patient (12.5%). The therapeutic effect of ICT and CRT was suggested to be useful for patients with advanced cervical esophageal cancer because it was performed safely with no serious adverse effect and the outcome of ICT predicted the effect of the subsequent CRT.
Suzuki
Tomoyoshi
T
Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Miura
Akinori
A
Kato
Tsuyoshi
T
Izumi
Yosuke
Y
Monma
Kumiko
K
Kawano
Tatsuyuki
T
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil